Klaria Pharma Holding AB Cash Flow Conversion Efficiency
Klaria Pharma Holding AB cash flow conversion efficiency. Based on the latest financial reports, Klaria Pharma Holding AB (KLAR) has a cash flow conversion efficiency ratio of 0.004x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-82.00K ≈ $-8.82K USD) by net assets (Skr-20.61 Million ≈ $-2.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Klaria Pharma Holding AB (2015–2025)
Cash flow conversion efficiency of Klaria Pharma Holding AB from 2015 to 2025. This chart illustrates how Klaria Pharma Holding AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Klaria Pharma Holding AB share price for real-time trading data and today's change.
Klaria Pharma Holding AB Cash Flow Conversion Ratio Explained
Klaria Pharma Holding AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Klaria Pharma Holding AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Klaria Pharma Holding AB ranked by their cash flow conversion efficiency. Also see KLAR market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Stingray Group Inc
TO:RAY-B
|
0.116x |
|
Alps Industries Limited
NSE:ALPSINDUS
|
-2.316x |
|
Tempo Inti Media Tbk
JK:TMPO
|
-0.034x |
|
B.V. Delftsch Aardewerkfabriek "De Porceleyne Fles Anno 1653"
AS:PORF
|
0.002x |
|
Compass Gold Corp
V:CVB
|
-0.005x |
|
Aegis Brands Inc
TO:AEG
|
0.013x |
|
TG Metals Ltd
AU:TG6
|
-0.028x |
|
S-Fuelcell co. Ltd
KQ:288620
|
-0.034x |
Annual Cash Flow Conversion Efficiency for Klaria Pharma Holding AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Klaria Pharma Holding AB from 2015 to 2025. Review Klaria Pharma Holding AB free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr-3.88 Million ≈ $-417.44K |
Skr-35.04 Million ≈ $-3.77 Million |
9.032x | +350.12% |
| 2024-12-31 | Skr3.31 Million ≈ $355.67K |
Skr-11.94 Million ≈ $-1.28 Million |
-3.611x | -1539.91% |
| 2023-12-31 | Skr41.13 Million ≈ $4.43 Million |
Skr-9.06 Million ≈ $-974.79K |
-0.220x | +66.31% |
| 2022-12-31 | Skr76.08 Million ≈ $8.19 Million |
Skr-49.73 Million ≈ $-5.35 Million |
-0.654x | -82.97% |
| 2021-12-31 | Skr69.42 Million ≈ $7.47 Million |
Skr-24.80 Million ≈ $-2.67 Million |
-0.357x | -10.92% |
| 2020-12-31 | Skr109.59 Million ≈ $11.79 Million |
Skr-35.30 Million ≈ $-3.80 Million |
-0.322x | -78.73% |
| 2019-12-31 | Skr82.11 Million ≈ $8.84 Million |
Skr-14.80 Million ≈ $-1.59 Million |
-0.180x | -86.99% |
| 2018-12-31 | Skr94.70 Million ≈ $10.19 Million |
Skr-9.13 Million ≈ $-982.10K |
-0.096x | -22.67% |
| 2017-12-31 | Skr153.52 Million ≈ $16.52 Million |
Skr-12.06 Million ≈ $-1.30 Million |
-0.079x | +12.65% |
| 2016-12-31 | Skr160.04 Million ≈ $17.22 Million |
Skr-14.39 Million ≈ $-1.55 Million |
-0.090x | -254.52% |
| 2015-12-31 | Skr174.59 Million ≈ $18.79 Million |
Skr-4.43 Million ≈ $-476.63K |
-0.025x | -- |
About Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction. T… Read more